ArticleIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Correlation of hepatic steatosis and fibrosis with microvascular complications among obese and non-obese individuals with T2D and MASLD.
Article in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized in non-obese individuals but remains poorly studied in people with type-2 diabetes (T2D), particularly in India. The study aimed at comparing hepatic steatosis, fibrosis and diabetes-related complications between non-obese (n, 150) and obese (n, 300) individuals with T2D.
methodsThis was a comparative cross-sectional study in which the participants underwent clinical, biochemical and anthropometric assessments. Hepatic steatosis and fibrosis were evaluated using ultrasonography and transient elastography, with controlled attenuation parameter (CAP) and liver stiffness (kPa) measurements as key indicators. Diabetes-related complications were assessed using standardized protocols.
resultsNon-obese individuals had higher retinopathy prevalence (18%) compared to obese individuals (8%), though this difference was non-significant (p = 0.141). Peripheral neuropathy was significantly more prevalent in non-obese (50.60%) vs. obese individuals (32%, p = 0.035), even after adjusting for confounders such as smoking and duration of diabetes. While CAP and kPa values were significantly higher in obese individuals, notable proportions of non-obese participants exhibited hepatic involvement-35% had CAP > 297 dB/m and 23% had liver stiffness ≥8.2 kPa. Among non-obese individuals, liver stiffness ≥9.7 kPa was associated with higher peripheral neuropathy. The FibroScan-AST score differed significantly between groups (p < 0.001). Non-obese participants had a higher proportion of low-risk scores (78% vs. 59.2%), but 22% still showed intermediate- or high-risk.
conclusionsAlthough obese individuals showed quantitatively higher CAP and liver stiffness values, non-obese individuals with T2D also exhibited clinically meaningful hepatic steatosis and fibrosis. Among the diabetes-related complications, peripheral neuropathy was the only complication that was more prevalent in the non-obese group. CLINICAL TRIAL REGISTRY NUMBER: CTRI/2023/06/054199.
Indexed as
Identifiers
42616340What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.